Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve Pubget Overpricing |
lüll Novel therapies for hypereosinophilic syndromes Antoniu SANeth J Med 2010[Aug]; 68 (1): 304-10BACKGROUND: Conventional therapies (corticosteroids, cytotoxic agents or interferon-a) or newer compounds such imatinib are used specifically in subsets of hypereosinophilic syndromes (HES). However other therapies are still needed in this condition. OBJECTIVE: To review the novel therapies for HES discussing their advantages and shortcomings. METHODS AND RESULTS: Preclinical and clinical data on novel tyrosine kinase inhibitors, anti-IL -5 antibodies or anti-CD52 antibodies (alemtuzumab) are analysed. The former might represent appropriate options in case of imatinib resistance; the efficacy of anti-IL-5 monoclonal antibodies therapy is limited by the occurrence of rebound eosinophilia and alemtuzumab might be a promising anti-eosinophil therapy for all HES subsets. CONCLUSION: Some of the novel therapies might become appropriate therapeutic options for HES.|Adrenal Cortex Hormones/*therapeutic use[MESH]|Alemtuzumab[MESH]|Antibodies, Monoclonal, Humanized[MESH]|Antibodies, Monoclonal/*therapeutic use[MESH]|Antibodies, Neoplasm/therapeutic use[MESH]|Antigens, CD/immunology[MESH]|Antigens, Neoplasm/immunology[MESH]|Antineoplastic Agents/*therapeutic use[MESH]|Benzamides[MESH]|Benzenesulfonates/therapeutic use[MESH]|Bone Marrow Transplantation[MESH]|CD52 Antigen[MESH]|Glycoproteins/antagonists & inhibitors/immunology[MESH]|Humans[MESH]|Hypereosinophilic Syndrome/*drug therapy/therapy[MESH]|Imatinib Mesylate[MESH]|Immunologic Factors/*therapeutic use[MESH]|Interferon-alpha/*therapeutic use[MESH]|Interleukin-5/antagonists & inhibitors/immunology[MESH]|Niacinamide/analogs & derivatives[MESH]|Phenylurea Compounds[MESH]|Piperazines/therapeutic use[MESH]|Protein Kinase Inhibitors/therapeutic use[MESH]|Protein-Tyrosine Kinases/antagonists & inhibitors[MESH]|Pyridines/therapeutic use[MESH]|Pyrimidines/therapeutic use[MESH]|Sorafenib[MESH] |